Webcasts | November 19, 2026
This recording is the final part of a three-part CLE series following a single life sciences collaboration and licensing dispute across its full lifecycle to explore how contract language, forum selection, and science shape leverage, timing, proof, and outcomes. In this session our lawyers turn to proof, where science drives both liability and value. We address technical and patent evidence, expert strategy, and the milestone and diligence disputes that drive outcomes in these types of matters.
MCLE CREDIT INFORMATION:
This program has been approved for credit in accordance with the requirements of the New York State Continuing Legal Education Board for a maximum of 1.0 credit hour, of which 1.0 credit hour may be applied toward the areas of professional practice requirement. This course is approved for transitional/non-transitional credit.
Attorneys seeking New York credit must obtain an Affirmation Form prior to watching the archived version of this webcast. Please contact [email protected] to request the MCLE form.
Gibson, Dunn & Crutcher LLP certifies that this activity has been approved for MCLE credit by the State Bar of California in the amount of 1.0 hour in the General Category.
California attorneys may claim “self-study” credit for viewing the archived version of this webcast. No certificate of attendance is required for California “self-study” credit.
MODERATOR:
Ryan Murr is widely recognized as one of the nation’s leading corporate lawyers in the life sciences industry. Over his career, he has advised on more than 500 transactions representing over $100 billion in aggregate transaction value, spanning mergers and acquisitions, capital markets, royalty monetizations, and structured financings, reflecting a combination of scale and breadth matched by few practices in the United States.
PANELISTS:
Charlotte Jacobsen is a USPTO-qualified, first-chair litigator with advanced scientific degrees and a deep understanding of chemistry, biology and biotechnology. For 20 years, Charlotte has represented clients in complex chemical, pharmaceutical and biotechnology patent and licensing disputes. She has been lead trial counsel and won cases in the federal district courts, before the Court of Appeals for the Federal Circuit, and between parties review proceedings before the Patent Trial and Appeal Board. She also has experience with arbitrations before the American Arbitration Association (AAA) and the International Chamber of Commerce (ICC), and with pre-litigation work having handled comprehensive preparatory investigations for numerous blockbuster products.
Mary Beth Maloney is a first-chair trial lawyer for public companies, their boards, and senior executives in their highest-stakes federal and state court litigation, securities matters, government enforcement actions, and complex commercial disputes, with a particular focus on healthcare, life sciences, and financial services. She is regularly retained as lead trial counsel when public companies face existential threats—from regulators and watchdog organizations, in securities class actions and SEC enforcement matters, and in bet-the-company commercial disputes.
© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com.
Attorney Advertising: These materials were prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and circumstances may vary, and prior results do not guarantee a similar outcome.
Source: www.gibsondunn.com



